Tissue-type plasminogen activator (t-PA) is less active in vivo and in vitro against clots that are enriched in platelets, even at therapeutic concentrations. The release of radioactivity from 125I-fibrin-labeled clots was decreased by 47% 6 hours after the addition of t-PA 400 U/mL when formed in platelet-rich versus platelet-poor plasma. This difference was not due to the release of plasminog...

OBJECTIVES Hematoma quality (especially the fibrin matrix) plays an important role in the bone healing process. Here, we investigated the effect of interleukin-1 beta (IL-1β) on fibrin clot formation from platelet-poor plasma (PPP). METHODS Five-milliliter of rat whole-blood samples were collected from the hepatic portal vein. All blood samples were firstly standardized via a thrombelastograp...

OBJECTIVE Abdominal aortic aneurysm (AAA) is characterized by widening of the aorta. Once the aneurysm exceeds 5.5 cm, there is a 10% risk of death due to rupture. AAA is also associated with mortality due to other cardiovascular disease. Our aim was to investigate clot structure in AAA and its relationship to aneurysm size. METHODS AND RESULTS Plasma was obtained from 49 controls, 40 patient...

Aims To determine if clotting, platelet, and endothelial function were affected by simulated short-haul commercial air flight conditions (SF) in participants with type 2 diabetes (T2DM) compared to controls. Methods 10 participants with T2DM (7 females, 3 males) and 10 controls (3 females, 7 males) completed the study. Participants were randomized to either spend 2 h in an environmental chamb...

In a previous study, we demonstrated unique secretory dynamics of tissue plasminogen activator (tPA) in which tPA was retained on the cell surface in a heavy chain-dependent manner after exocytosis from secretory granules in vascular endothelial cells. Here, we examined how retained tPA expresses its enzymatic activity. Retained tPA effectively increased the lysine binding site-dependent bindin...

Background—Factor V (fV) predisposes to thrombosis by enhancing thrombin formation. This study tested the hypothesis that fV inhibits fibrinolysis in vivo. Methods and Results—Radiolabeled clots were injected into the jugular veins of wild-type mice and mice heterozygous (fV ) or homozygous (fV) for fV. Mean percent clot lysis 5 hours later was significantly reduced in fV mice (14.3 3.6%, n 13)...

UNLABELLED There are several clot lysis tests available to assess the presence of increased fibrinolysis in a clinical situation. These include whole blood, plasma, and "eugloblin" lysis tests. The euglobulin lysis test (ELT) is actually a modified plasma clot lysis time, which detects increased plasminogen activation and subsequent fibrinolysis. It does not detect the activity of antiplasmins....